Cecilia Jiménez Mallebrera

Cecilia Jiménez Mallebrera

Jefe de Grupo Senior

Researcher Cecilia Jiménez graduated in Biology from the University of Navarra and from the University of Buckingham in 1996 and earned her PhD in Genetics from the University of London (UCL) in 2001. In 2005, she obtained the degree of Clinical Scientist for the Health and Care Professions Council of the United Kingdom.

Between 2001 and 2010, she undertook a postdoctoral stay at the Dubowitz Neuromuscular Center (now in Great Ormond Street Hospital, London) and the Dept. Of Neuropathology at the Charing Cross Hospital, London where she specialized in neuromuscular pathologies and in the genetics and mechanisms of congenital muscular dystrophies.

She is a member of the European networks EURO-NMD and Treat-NMD and CIBERER.

In 2010, she joined as Researcher Miguel-Servet and group leader at the FSJD.
She is currently leading the group of applied research in neuromuscular diseases whose main objectives are to deepen the mechanism by which neuromuscular diseases occur, to improve the diagnosis of patients by identifying new biomarkers and methodologies and to investigate advanced therapies based, among others, on the genetic edition.
 

cecilia.jimenez@sjd.es

Last Publications

More Publications

Projects

Project name:
A nanomedicine platform for delivery of antisense oligonucleotides to treat neuromuscular diseases
Leader
Cecilia Jiménez Mallebrera
Funding entities:
Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
Code
2023 LLAV 00079
Starting - finishing date:
2024 - 2024
Project name:
Role of CMG2 and its associated effectors as potential therapeutic targets and in the pathophysiology of congenital muscular dystrophies due to collagen VI deficiency
Leader
Cecilia Jiménez Mallebrera
Funding entities:
Alexion Pharmaceuticals Inc.
Code
PCP00387
Starting - finishing date:
2023 - 2026
Project name:
Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos
Leader
Cecilia Jiménez Mallebrera
Funding entities:
Fundación Noelia. Niños Contra la Distrofia Muscular Congénita por Déficit de Colágeno VI
Code
PFNR0182
Starting - finishing date:
2023 - 2025
More projects

News

See All news